久久久久免费_精品国产乱码久久久久久久软件_欧美一区亚洲一区_国产一区二区三区高清在线观看_欧美日在线观看_成人网av

英國葛蘭素史克GSK GlaxoSmithKline 葛蘭素史克中國    葛蘭素史克全球    
葛蘭素史克公司，由葛蘭素威康（Glaxo Wellcome）和史克必成（SmithKline Beecham）強強聯(lián)合,于2000年12月成立。  
作為世界領(lǐng)先的制藥業(yè)巨擘，葛蘭素史克公司秉承以研究開發(fā)為基礎(chǔ)的一貫理念，憑藉公司本身的技術(shù)潛力和資源優(yōu)勢，在當(dāng)今瞬息萬變的醫(yī)療保健領(lǐng)域保持強勁的增長勢頭。葛蘭素史克公司的歷史可追溯至18世紀(jì)，經(jīng)歷兩個多世紀(jì)的不斷創(chuàng)新和數(shù)次合并，葛蘭素威康和史克必成于2000年12月強強聯(lián)合，在醫(yī)藥領(lǐng)域確立了世界級的領(lǐng)先地位。
      葛蘭素史克公司總部設(shè)在英國，以美國為業(yè)務(wù)營運中心，在全球藥品市場中約占近7%的份額。公司在全球擁有10萬余名既掌握專業(yè)技能又有奉獻(xiàn)精神的出色員工，在世界37個國家擁有82個生產(chǎn)基地，年產(chǎn)藥品40億盒，產(chǎn)品遍及全球市場。2006年，葛蘭素史克全球銷售總額達(dá)232億英鎊，按恒定匯率同比增長9%。

葛蘭素史克公司的藥品主要用于六大領(lǐng)域――抗哮喘、抗病毒、抗感染、精神衛(wèi)生、糖尿病和消化系統(tǒng)，癌癥藥物的研發(fā)也正迅猛發(fā)展。葛蘭素史克的疫苗產(chǎn)品居世界領(lǐng)先地位，全球25%的疫苗是由葛蘭素史克提供的。此外，在消費保健品領(lǐng)域，葛蘭素史克亦居世界前列，主要產(chǎn)品包括非處方藥、口腔護(hù)理產(chǎn)品、戒煙產(chǎn)品和營養(yǎng)保健飲料。
葛蘭素史克中國
葛蘭素史克公司在中國的歷史最早可追溯至20世紀(jì)初葉。自20世紀(jì)80年代以來，在中國政府改革開放政策的感召下，公司在中國積極投資，將最先進(jìn)的制藥技術(shù)、最優(yōu)質(zhì)的產(chǎn)品、最新型的商業(yè)模式、最現(xiàn)代化的管理理念和市場營銷技巧引入了中國。

葛蘭素威康和史克必成公司于2000年12月完成全球性合并，2002年，葛蘭素史克(中國)投資有限公司全面完成業(yè)務(wù)整合并正式宣布成立，成為中國目前規(guī)模最大的跨國制藥企業(yè)之一。公司業(yè)務(wù)由處方藥、非處方藥、疫苗和消費保健品4大部分組成，投資公司和地區(qū)總部位于北京，主要業(yè)務(wù)中心分設(shè)在上海、天津和香港。

葛蘭素史克是最早在中國成功興建合資企業(yè)的外國制藥公司之一。在進(jìn)入中國的20多年間，葛蘭素史克先后成立了5家公司，目前2家為合資企業(yè)，總注冊資本超過2.3億美元。目前公司在全國28個主要城市(包括香港)設(shè)立了辦事機構(gòu)，在全國擁有近3000名員工，為中國的醫(yī)藥行業(yè)培養(yǎng)了一大批高素質(zhì)的商業(yè)管理人員和技術(shù)骨干。

We have a challenging and inspiring mission: to improve the quality of human life by enabling people to do more, feel better and live longer. This mission gives us the purpose to develop innovative medicines and products that help millions of people around the world.

We are one of the few pharmaceutical companies researching both medicines and vaccines for the World Health Organization’s three priority diseases – HIV/AIDS, tuberculosis and malaria, and are very proud to have developed some of the leading global medicines in these fields.

Headquartered in the UK and with operations based in the US, we are one of the industry leaders, with an estimated seven per cent of the world's pharmaceutical market.

But being a leader brings responsibility. This means that we care about the impact that we have on the people and places touched by our mission to improve health around the world.

It also means that we must help developing countries where debilitating disease affects millions of people and access to life-changing medicines and vaccines is a problem. To meet this challenge, we are committed to providing discounted medicines where they are needed the most.

As a company with a firm foundation in science, we have a flair for research and a track record of turning that research into powerful, marketable drugs. Every hour we spend more than ￡300,000 (US$562,000) to find new medicines.

We produce medicines that treat six major disease areas – asthma, virus control, infections, mental health, diabetes and digestive conditions. In addition, we are a leader in the important area of vaccines and are developing new treatments for cancer.

GSK worldwide
GlaxoSmithKline (GSK) is a leading, research-based pharmaceutical company with a powerful combination of skills and resources that provides a platform for delivering strong growth in today's rapidly changing healthcare environment.

GSK's history can be traced back to the 18th century. By the end of the 20th century, due to the successful merger of two global pharmaceutical giants, Glaxo Wellcome and SmithKline Beecham, GSK is well positioned to become the indisputable leader of the pharmaceutical industry worldwide.

Headquartered in the UK and with operations based in the US, GSK is one of the industry leaders, with an estimated seven per cent of the world's pharmaceutical market. The company's total sales for 2006 were ￡23.2 billion, up 9% in CER terms. GSK has 82 manufacturing sites in 37 countries that supply products to the global markets. GSK has over 100,000 highly skilled and dedicated employees worldwide.

GSK produces medicines that treat six major disease areas ---- asthma, virus control, infections, mental health, diabetes and digestive conditions. In addition, we are a leader in the important area of vaccines and are developing new treatments for cancer. GSK also has a Consumer Healthcare portfolio comprising over-the-counter (OTC) medicines, dental products, smoking control products and nutritional healthcare drinks.

A long and successful heritage in China
GSK's history in China can be traced back to the early 20th century. Since the 1980s, GSK has actively invested in China by contributing state-of-the-art pharmaceutical technologies, innovative products, new business models, modern management concepts and sales and marketing skills. 

Since the completion of the global merger between Glaxo Wellcome and SmithKline Beecham in December 2000, GSK has maintained a leading position within the pharmaceutical community. In 2002, GlaxoSmithKline (China) Investment Co. Ltd. was officially established and became one of the largest multinational pharmaceutical companies in China.

Among its major business units in China, Prescription Medicines, Vaccines, Over-the-Counter (OTC) Medicines and Consumer Healthcare are headquartered separately in Shanghai, Tianjin and Hong Kong. Beijing is also the base and area centre for the holding company GlaxoSmithKline (China) Investment Co. Ltd.

GSK is one of the first foreign pharmaceutical companies to establish successful joint ventures in China. To date, more than twenty years after its initial investment in China, GSK has established five companies with a total registered capital of US$230 million. The various companies continue to create jobs and provide training for business managers and professional staff in the pharmaceutical industry, as well as provide business opportunities to local partners and medical professionals.

Currently, GSK China has offices in twenty-eight major cities (including Hong Kong) and five legal entities encompassing four manufacturing facilities, two joint ventures and near 3000 employees nationwide.